These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1768568)

  • 1. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.
    Pirmohamed M; Graham A; Roberts P; Smith D; Chadwick D; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1991 Dec; 32(6):741-9. PubMed ID: 1768568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.
    Shear NH; Spielberg SP
    J Clin Invest; 1988 Dec; 82(6):1826-32. PubMed ID: 3198757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity.
    Zakrzewska JM; Ivanyi L
    J Allergy Clin Immunol; 1988 Jul; 82(1):110-5. PubMed ID: 3392362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin.
    Riley RJ; Maggs JL; Lambert C; Kitteringham NR; Park BK
    Br J Clin Pharmacol; 1988 Nov; 26(5):577-88. PubMed ID: 3207562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenytoin and carbamazepine cross reactivity: report of a case and review of literature.
    Misra UK; Kalita J; Rathore C
    Postgrad Med J; 2003 Dec; 79(938):703-4. PubMed ID: 14707249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug interactions in children taking oxcarbazepine.
    Sallas WM; Milosavljev S; D'souza J; Hossain M
    Clin Pharmacol Ther; 2003 Aug; 74(2):138-49. PubMed ID: 12891224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta.
    Myllynen P; Pienimäki P; Raunio H; Vähäkangas K
    Hum Exp Toxicol; 1998 Dec; 17(12):668-76. PubMed ID: 9988371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial occurrence of hypersensitivity to phenytoin.
    Gennis MA; Vemuri R; Burns EA; Hill JV; Miller MA; Spielberg SP
    Am J Med; 1991 Dec; 91(6):631-4. PubMed ID: 1750433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity.
    Pirmohamed M; Kitteringham NR; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1992 Feb; 33(2):183-6. PubMed ID: 1550698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro.
    Pirmohamed M; Kitteringham NR; Guenthner TM; Breckenridge AM; Park BK
    Biochem Pharmacol; 1992 Apr; 43(8):1675-82. PubMed ID: 1575766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents.
    Seitz CS; Pfeuffer P; Raith P; Bröcker EB; Trautmann A
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):698-702. PubMed ID: 17165282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic parameters of lymphocyte microsomal epoxide hydrolase in carbamazepine hypersensitive patients. Assessment by radiometric HPLC.
    Davis CD; Pirmohamed M; Kitteringham NR; Allott RL; Smith D; Park BK
    Biochem Pharmacol; 1995 Oct; 50(9):1361-6. PubMed ID: 7503784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction.
    Soskin DP; Kane AJ; Stern TA
    Psychosomatics; 2010; 51(6):532-5. PubMed ID: 21051688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers.
    Mecarelli O; Vicenzini E; Pulitano P; Vanacore N; Romolo FS; Di Piero V; Lenzi GL; Accornero N
    Ann Pharmacother; 2004 Nov; 38(11):1816-22. PubMed ID: 15367726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro.
    Sorrell TC; Forbes IJ
    Clin Exp Immunol; 1975 May; 20(2):273-85. PubMed ID: 1212810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity.
    Green VJ; Pirmohamed M; Kitteringham NR; Gaedigk A; Grant DM; Boxer M; Burchell B; Park BK
    Biochem Pharmacol; 1995 Oct; 50(9):1353-9. PubMed ID: 7503783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome.
    Kim CW; Choi GS; Yun CH; Kim DI
    J Korean Med Sci; 2006 Aug; 21(4):768-72. PubMed ID: 16891830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes.
    Castrén K; Pienimäki P; Arvela P; Vähäkangas K
    Hum Exp Toxicol; 1996 Jul; 15(7):577-82. PubMed ID: 8818711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions.
    Leeder JS; Riley RJ; Cook VA; Spielberg SP
    J Pharmacol Exp Ther; 1992 Oct; 263(1):360-7. PubMed ID: 1403797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro.
    Riley RJ; Kitteringham NR; Park BK
    Br J Clin Pharmacol; 1989 Oct; 28(4):482-7. PubMed ID: 2590607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.